|Bid||2.6000 x 900|
|Ask||2.7600 x 2200|
|Day's Range||2.6026 - 2.9000|
|52 Week Range||2.2700 - 29.7500|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.33|
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Acorda (ACOR) delivered earnings and revenue surprises of 48.11% and 91.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ARDSLEY, N.Y.-- -- INBRIJA™ 2Q 2019 net sales of $3.0 million CHMP issues positive opinion on INBRIJA AMPYRA ® 2Q 2019 net sales of $44.0 million Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2019. “We made significant progress on the launch of Inbrija during the second quarter. Effective May 24, 2019, Inbrija became preferred on the Express Scripts ...
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Acorda Therapeutics, Inc. (ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending INBRIJA’s approval by the European Commission (EC). The recommended indication is: Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. INBRIJA was approved by the U.S. Food and Drug Administration on December 21, 2018 for the intermittent treatment of OFF episodes (also known as OFF periods) in people with Parkinson’s disease treated with carbidopa/levodopa.
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.